(mo)BETTA Trial in Transwomen for Optimization of ART
NCT03348163 is a phase 4 interventional trial sponsored by The University of Texas Health Science Center, Houston. As of 21 Nov 2026, it was terminated. It studies B/FTC/TAF and Current ART in HIV Infections. The registry lists an enrollment of 26 participants at 1 site in 1 country. The registry lists a start date of 6 Jun 2018 and a primary completion date of 15 Dec 2020. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03348163 |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | The University of Texas Health Science Center, Houston |
| Enrollment | 26 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | HIV Infections |
| Drugs | B/FTC/TAF and Current ART |
| Start | 6 Jun 2018 |
| Primary completion | 15 Dec 2020 |
| Study completion | 15 Dec 2020 |
| Last update posted | 3 Oct 2022 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jordan E Lake, MD
The University of Texas Health Science Center, Houston
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Thomas Street Health Center
Houston
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03348163
Each answer restates registry values shown on this page.
What is NCT03348163?
NCT03348163 is a phase 4 interventional trial sponsored by The University of Texas Health Science Center, Houston. It studies B/FTC/TAF and Current ART in HIV Infections.
Who leads NCT03348163?
The registry names Jordan E Lake, MD (principal investigator, The University of Texas Health Science Center, Houston) as the overall official.
Where does NCT03348163 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03348163 study?
The registered drug and biological interventions are B/FTC/TAF and Current ART.
When did NCT03348163 end?
The registry lists a primary completion date of 15 Dec 2020 and a study completion date of 15 Dec 2020. The sponsor last updated the record on 3 Oct 2022.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.